文献速递免疫规划传染病防控与疫情报告

重组黑猩猩腺病毒疫苗对PRRSV NADC30的保护效果

Effective protection against PRRSV NADC30 by recombinant chimpanzee adenovirus vaccines expressing GP35 or M-GP5 fusion proteins.
PubMed 文献 · Vaccine · 2026-09-11

本研究构建了表达PRRSV NADC30样株GP35或M-GP5融合蛋白的两株重组黑猩猩腺病毒疫苗候选(rChAd-30-GP35与rChAd-30-M-GP5)。小鼠与仔猪接种后诱发了较强的抗原特异性免疫应答,包括GP5特异性抗体、中和活性与T细胞免疫;仔猪攻毒后获得有效保护,在若干关键效力指标上优于商品化灭活疫苗。

要点

  • 重组腺病毒疫苗在小鼠和仔猪中诱导GP5特异性抗体、中和活性及T细胞免疫。
  • 仔猪攻毒后重组疫苗获有效保护,多项关键效力指标优于商品化灭活疫苗。
  • 结果支持黑猩猩腺病毒载体用于PRRSV新型基因工程疫苗开发。

核心结论

  • 表达GP35或M-GP5融合蛋白的重组黑猩猩腺病毒疫苗可诱导强抗原特异性免疫并对PRRSV NADC30攻毒提供有效保护。
  • 该载体平台为开发更安全有效的下一代PRRSV疫苗及快速适配新流行株提供了基础。

研究设计与样本

  • 研究构建两株重组黑猩猩腺病毒疫苗候选rChAd-30-GP35和rChAd-30-M-GP5,分别表达PRRSV NADC30样株的GP35与M-GP5融合蛋白。
  • 在小鼠和仔猪两种模型中进行接种评价,并在仔猪中进行病毒攻毒保护试验,与商品化灭活疫苗比较。

主要发现

  • 接种重组腺病毒后小鼠和仔猪均产生较强抗原特异性免疫应答,包括增强的GP5特异性抗体产生、中和活性及T细胞介导免疫。
  • 仔猪攻毒后重组腺病毒疫苗引发有效保护,并在若干关键效力参数上优于商品化灭活疫苗。

临床怎么用

  • 提示重组黑猩猩腺病毒载体可作为PRRSV基因工程疫苗的候选平台,用于替代或补充现有灭活与弱毒疫苗。
  • 融合抗原设计(GP35扩展表位覆盖、M-GP5稳定GP5构象)为改善GP5免疫原性受限问题提供思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine Reproductive and Respiratory Syndrome (PRRS) is one of the highly contagious infectious diseases caused by Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) that seriously harms the pig industry. Existing commercial inactivated and live attenuated PRRSV vaccines have very limited protective efficacy, with weak neutralizing antibody and cell-mediated immune responses, and risks of vaccine strain virulence reversion. PRRSV GP5, a key biological macromolecular antigen for neutralizing antibody induction, has complex immunogenicity and limited vaccine utility due to hypervariable regions, glycosylation changes, and narrow neutralizing epitopes. In contrast, the fusion antigen GP35 (GP3 and GP5) and M-GP5 (M and GP5) offer complementary improvements via expanded epitope coverage and stabilized GP5 conformation, respectively. In this study, we constructed two recombinant chimpanzee adenovirus vaccine candidates, rChAd-30-GP35 and rChAd-30-M-GP5, to express the GP35 or M-GP5 fusion proteins of the PRRSV NADC30-like strain. Vaccination with the recombinant adenovirus in both mouse and piglet models resulted in a potent antigen-specific immune response, including enhanced GP5-specific antibody production, neutralizing activity, and T-cell-mediated immunity. Furthermore, following viral challenge, the recombinant adenovirus vaccine elicited effective protection in piglets and outperformed a commercial inactivated vaccine in several critical efficacy parameters. Our results emphasize the importance and feasibility of recombinant chimpanzee adenovirus vector platforms in the development of novel genetic engineering vaccines for PRRSV. Collectively, this work provides a foundation for the development of next-generation safer and more effective PRRSV vaccines and offers a versatile platform for rapidly adapting vaccine designs to emerging field strains.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu C, Ma P, Li J, et al. Effective protection against PRRSV NADC30 by recombinant chimpanzee adenovirus vaccines expressing GP35 or M-GP5 fusion proteins. Vaccine. 2026. PMID: 42727398. doi:10.1016/j.vaccine.2026.129158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。